IP Library Granted Patent US 8,188,232
Granted Patent B1
US 8,188,232 · App. 11/719,356 · Granted May 29, 2012

Compositions and methods for modulating lymphocyte activity

Assignee: Washington University in St. Louis
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,188,232
App. No.
11/719,356
Granted
May 29, 2012
Kind
B1
Abstract

The invention derives from the identification of HVEM as the native ligand for BTLA. The invention provides compositions and methods for modulating BTLA-HVEM interactions and BTLA and HVEM activity, which are useful for modulating immune responses. Agonists and antagonists of the BTLA-HVEM interaction are provided, and methods of treating a variety of conditions through the modulation of immune responses are provided.

Claims (4)

1. An antibody that specifically binds to a protein comprising the amino acid sequence set forth in SEQ ID NO:2, wherein the antibody is capable of reducing or eliminating phosphorylation of intracellular domain tyrosine residues of said protein or binding of said protein to SHP-2, wherein the antibody is capable of reducing binding of said protein to an HVEM protein.

2. An anti-BTLA antibody capable of reducing or eliminating phosphorylation of BTLA intracellular domain tyrosine residues or binding of BTLA to SHP-2, wherein the antibody is capable of reducing binding of the protein comprising the amino acid sequence set forth in SEQ ID NO: 2 to an HVEM protein.

3. An antibody that specifically binds to an epitope in the Ig domain of a BTLA protein, the BTLA protein comprising the amino acid sequence set forth in SEQ ID NO:2, wherein the antibody is capable of reducing or eliminating phosphorylation of BTLA intracellular domain tyrosine residues or binding of BTLA to SHP-2, wherein the antibody is capable of reducing binding of the protein comprising the amino acid sequence set forth in SEQ ID NO: 2 to an HVEM protein.

4. An antibody that specifically binds to an epitope of a human BTLA protein, the epitope comprising one or more residues selected from the group consisting of V36, Q37, L38, L49, E57, C79, K93, and S96 of SEQ ID NO:2, wherein the antibody is capable of reducing or eliminating phosphorylation of BTLA intracellular domain tyrosine residues or binding of BTLA to SHP-2, and wherein the antibody is capable of reducing binding of the protein comprising the amino acid sequence set forth in SEQ ID NO: 2 said to an HVEM protein.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 22, 2016
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040662/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2007
From: MURPHY, KENNETH M.; MURPHY, THERESA L.; SEDY, JOHN R.; HURCHLA, MICHELLE A.
To: WASHINGTON UNIVERSITY IN ST. LOUIS
Reel/Frame 020182/0701 →
Continuity (1)
Provisional Application 60628474 · Nov 15, 2004